Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (11): 1130-1135.DOI: 10.3969/j.issn.1673-8640.2020.11.011
Previous Articles Next Articles
ZHENG Sihan1, LIU Mingcong1, LUAN Liang2, LIU Jing2, TIAN Xiao2, LIU Yameng3, WAN Nan2
Received:
2020-04-08
Online:
2020-11-30
Published:
2020-12-01
CLC Number:
ZHENG Sihan, LIU Mingcong, LUAN Liang, LIU Jing, TIAN Xiao, LIU Yameng, WAN Nan. Analysis of routine biochemical indicators in 1 743 patients with corona virus disease 2019 in Wuhan[J]. Laboratory Medicine, 2020, 35(11): 1130-1135.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.11.011
组别 | hs-cTnT | cTnI | CK | CK-MB | MYO | LDH | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | ||||||
非重症组 | 548 | 151(27.55) | 368 | 9 (2.45) | 1 187 | 155(13.06) | 1 662 | 29(1.74) | 721 | 45(6.24) | 1 680 | 87(5.18) | |||||
重症组 | 42 | 36(85.71) | 18 | 4(22.22) | 46 | 15(32.61) | 58 | 5 (8.62) | 44 | 21(47.73) | 59 | 32(54.24) | |||||
χ2值 | 60.950 | 20.623 | 14.240 | 13.674 | 90.538 | 215.195 | |||||||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||||||
组别 | Alb | A/G比值 | AST | ALT | DBil | IBil | |||||||||||
检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | ||||||
非重症组 | 1 684 | 329(19.54) | 1 684 | 1 250(74.23) | 1 223 | 133(10.87) | 319 | 100(31.35) | 1 683 | 17(1.01) | 1 683 | 312(18.54) | |||||
重症组 | 59 | 50(84.75) | 59 | 55(93.22) | 47 | 19(40.43) | 3 | 1(33.33) | 59 | 6(10.17) | 59 | 18(30.51) | |||||
χ2值 | 142.447 | 10.929 | 37.513 | 0.005 | 36.704 | 5.319 | |||||||||||
P值 | <0.001 | 0.001 | <0.001 | 0.678 | <0.001 | 0.021 | |||||||||||
组别 | TB | Cr | 尿素 | UA | K+ | Na+ | |||||||||||
检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | ||||||
非重症组 | 1 683 | 91(5.41) | 1 678 | 55(3.28) | 1 678 | 174(10.37) | 1 678 | 164(9.77) | 1 637 | 88(5.38) | 1 636 | 108(6.60) | |||||
重症组 | 59 | 8(13.56) | 59 | 7(11.86) | 59 | 19(32.20) | 59 | 5 (8.47) | 59 | 9(15.25) | 59 | 14(23.73) | |||||
χ2值 | 7.068 | 12.209 | 27.511 | 0.109 | 10.306 | 25.009 | |||||||||||
P值 | 0.008 | <0.001 | <0.001 | 0.741 | 0.001 | <0.001 |
组别 | hs-cTnT | cTnI | CK | CK-MB | MYO | LDH | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | ||||||
非重症组 | 548 | 151(27.55) | 368 | 9 (2.45) | 1 187 | 155(13.06) | 1 662 | 29(1.74) | 721 | 45(6.24) | 1 680 | 87(5.18) | |||||
重症组 | 42 | 36(85.71) | 18 | 4(22.22) | 46 | 15(32.61) | 58 | 5 (8.62) | 44 | 21(47.73) | 59 | 32(54.24) | |||||
χ2值 | 60.950 | 20.623 | 14.240 | 13.674 | 90.538 | 215.195 | |||||||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||||||
组别 | Alb | A/G比值 | AST | ALT | DBil | IBil | |||||||||||
检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | ||||||
非重症组 | 1 684 | 329(19.54) | 1 684 | 1 250(74.23) | 1 223 | 133(10.87) | 319 | 100(31.35) | 1 683 | 17(1.01) | 1 683 | 312(18.54) | |||||
重症组 | 59 | 50(84.75) | 59 | 55(93.22) | 47 | 19(40.43) | 3 | 1(33.33) | 59 | 6(10.17) | 59 | 18(30.51) | |||||
χ2值 | 142.447 | 10.929 | 37.513 | 0.005 | 36.704 | 5.319 | |||||||||||
P值 | <0.001 | 0.001 | <0.001 | 0.678 | <0.001 | 0.021 | |||||||||||
组别 | TB | Cr | 尿素 | UA | K+ | Na+ | |||||||||||
检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | 检测例数 | 阳性例数(%) | ||||||
非重症组 | 1 683 | 91(5.41) | 1 678 | 55(3.28) | 1 678 | 174(10.37) | 1 678 | 164(9.77) | 1 637 | 88(5.38) | 1 636 | 108(6.60) | |||||
重症组 | 59 | 8(13.56) | 59 | 7(11.86) | 59 | 19(32.20) | 59 | 5 (8.47) | 59 | 9(15.25) | 59 | 14(23.73) | |||||
χ2值 | 7.068 | 12.209 | 27.511 | 0.109 | 10.306 | 25.009 | |||||||||||
P值 | 0.008 | <0.001 | <0.001 | 0.741 | 0.001 | <0.001 |
组别 | hs-cTnT/(ng/mL) | cTnI/(ng/mL) | CK/(U/L) | CK-MB/(U/L) | |
---|---|---|---|---|---|
非重症组 | 6.86(3.89~15.27) | 0.00(0.00~0.00) | 51.94(38.02~74.07) | 8.04(6.09~10.33) | |
重症组 | 41.31(23.01~96.32) | 0.01(0.00~0.02) | 54.32(28.91~138.42) | 11.47(8.02~16.09) | |
Z值 | -8.267 | -5.182 | -0.558 | -5.120 | |
P值 | <0.001 | <0.001 | 0.577 | <0.001 | |
组别 | MYO/(ng/mL) | LDH/(U/L) | Alb/(g/L) | A/G比值 | AST/(U/L) |
非重症组 | 21.00(21.00~29.85) | 169.21(143.68~200.86) | 38.96(36.01~41.53) | 1.34 | 20.52(17.00~26.92) |
(1.17~1.50) | |||||
重症组 | 59.39(25.22~190.15) | 279.36(243.81~385.25) | 30.45(28.00~33.47) | 1.05 | 31.68(23.55~55.10) |
(0.89~1.26) | |||||
Z值 | -6.773 | -9.926 | -9.607 | -6.990 | -6.000 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | ALT/(U/L) | DBil/(μmol/L) | IBil/(μmol/L) | TB/(μmol/L) | Cr/(μmol/L) |
非重症组 | 25.35(16.54~41.41) | 2.13 | 8.58(6.86~10.97) | 10.7 | 55.14(45.74~66.87) |
(1.63~2.79) | (8.51~13.68) | ||||
重症组 | 39.01(29.28~72.72) | 3.77 | 9.33(8.59~12.61) | 13.77 | 57.99(41.25~74.85) |
(2.66~5.50) | (11.32~17.59) | ||||
Z值 | -1.903 | -7.690 | -3.083 | -4.893 | -0.222 |
P值 | 0.274 | <0.001 | 0.002 | <0.001 | 0.824 |
组别 | 尿素/(mmol/L) | UA/(μmol/L) | K+/(mmol/L) | Na+/(mmol/L) | |
非重症组 | 4.93(4.08~5.91) | 283.18(227.16~348.75) | 4.18(3.92~4.44) | 140.30(138.90~141.50) | |
重症组 | 5.89(4.64~8.63) | 192.48(142.43~317.31) | 4.10(3.61~4.37) | 138.90(137.05~140.95) | |
Z值 | -4.076 | -5.014 | -1.840 | -3.473 | |
P值 | <0.001 | <0.001 | 0.066 | 0.001 |
组别 | hs-cTnT/(ng/mL) | cTnI/(ng/mL) | CK/(U/L) | CK-MB/(U/L) | |
---|---|---|---|---|---|
非重症组 | 6.86(3.89~15.27) | 0.00(0.00~0.00) | 51.94(38.02~74.07) | 8.04(6.09~10.33) | |
重症组 | 41.31(23.01~96.32) | 0.01(0.00~0.02) | 54.32(28.91~138.42) | 11.47(8.02~16.09) | |
Z值 | -8.267 | -5.182 | -0.558 | -5.120 | |
P值 | <0.001 | <0.001 | 0.577 | <0.001 | |
组别 | MYO/(ng/mL) | LDH/(U/L) | Alb/(g/L) | A/G比值 | AST/(U/L) |
非重症组 | 21.00(21.00~29.85) | 169.21(143.68~200.86) | 38.96(36.01~41.53) | 1.34 | 20.52(17.00~26.92) |
(1.17~1.50) | |||||
重症组 | 59.39(25.22~190.15) | 279.36(243.81~385.25) | 30.45(28.00~33.47) | 1.05 | 31.68(23.55~55.10) |
(0.89~1.26) | |||||
Z值 | -6.773 | -9.926 | -9.607 | -6.990 | -6.000 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | ALT/(U/L) | DBil/(μmol/L) | IBil/(μmol/L) | TB/(μmol/L) | Cr/(μmol/L) |
非重症组 | 25.35(16.54~41.41) | 2.13 | 8.58(6.86~10.97) | 10.7 | 55.14(45.74~66.87) |
(1.63~2.79) | (8.51~13.68) | ||||
重症组 | 39.01(29.28~72.72) | 3.77 | 9.33(8.59~12.61) | 13.77 | 57.99(41.25~74.85) |
(2.66~5.50) | (11.32~17.59) | ||||
Z值 | -1.903 | -7.690 | -3.083 | -4.893 | -0.222 |
P值 | 0.274 | <0.001 | 0.002 | <0.001 | 0.824 |
组别 | 尿素/(mmol/L) | UA/(μmol/L) | K+/(mmol/L) | Na+/(mmol/L) | |
非重症组 | 4.93(4.08~5.91) | 283.18(227.16~348.75) | 4.18(3.92~4.44) | 140.30(138.90~141.50) | |
重症组 | 5.89(4.64~8.63) | 192.48(142.43~317.31) | 4.10(3.61~4.37) | 138.90(137.05~140.95) | |
Z值 | -4.076 | -5.014 | -1.840 | -3.473 | |
P值 | <0.001 | <0.001 | 0.066 | 0.001 |
项目 | AUC | P值 | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|---|
hs-cTnT | 0.881 | <0.001 | 13.61 ng/mL | 90.5 | 71.9 | 0.624 |
LDH | 0.880 | <0.001 | 243.32 U/L | 76.3 | 91.8 | 0.681 |
Alb | 0.867 | <0.001 | 34.80 g/L | 84.7 | 81.6 | 0.663 |
MYO | 0.799 | <0.001 | 38.60 ng/mL | 61.4 | 84.3 | 0.459 |
DBil | 0.794 | <0.001 | 2.50 μmol/L | 84.7 | 63.5 | 0.482 |
A/G比值 | 0.767 | <0.001 | 1.15 | 66.1 | 78.2 | 0.443 |
AST | 0.758 | <0.001 | 23.14 U/L | 78.7 | 63.1 | 0.418 |
cTnI | 0.750 | <0.001 | 0.01 ng/mL | 66.7 | 82.1 | 0.488 |
CK-MB | 0.697 | <0.001 | 11.36 U/L | 51.7 | 83.0 | 0.347 |
TB | 0.687 | <0.001 | 11.11 μmol/L | 78.0 | 53.4 | 0.314 |
尿素 | 0.656 | <0.001 | 6.36 mmol/L | 49.2 | 82.3 | 0.315 |
IBil | 0.618 | 0.002 | 8.32 μmol/L | 81.4 | 46.5 | 0.279 |
项目 | AUC | P值 | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|---|
hs-cTnT | 0.881 | <0.001 | 13.61 ng/mL | 90.5 | 71.9 | 0.624 |
LDH | 0.880 | <0.001 | 243.32 U/L | 76.3 | 91.8 | 0.681 |
Alb | 0.867 | <0.001 | 34.80 g/L | 84.7 | 81.6 | 0.663 |
MYO | 0.799 | <0.001 | 38.60 ng/mL | 61.4 | 84.3 | 0.459 |
DBil | 0.794 | <0.001 | 2.50 μmol/L | 84.7 | 63.5 | 0.482 |
A/G比值 | 0.767 | <0.001 | 1.15 | 66.1 | 78.2 | 0.443 |
AST | 0.758 | <0.001 | 23.14 U/L | 78.7 | 63.1 | 0.418 |
cTnI | 0.750 | <0.001 | 0.01 ng/mL | 66.7 | 82.1 | 0.488 |
CK-MB | 0.697 | <0.001 | 11.36 U/L | 51.7 | 83.0 | 0.347 |
TB | 0.687 | <0.001 | 11.11 μmol/L | 78.0 | 53.4 | 0.314 |
尿素 | 0.656 | <0.001 | 6.36 mmol/L | 49.2 | 82.3 | 0.315 |
IBil | 0.618 | 0.002 | 8.32 μmol/L | 81.4 | 46.5 | 0.279 |
项目 | B值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
hs-cTnT | 0.006 | 0.002 | 10.114 | 0.001 | 1.006 (1.002~1.009) |
Alb | -0.199 | 0.037 | 28.575 | 0.000 | 0.820 (0.762~0.882) |
LDH | 0.000 | 0.000 | 0.342 | 0.558 | 1.000(1.000~1.001) |
MYO | 0.000 | 0.001 | 0.079 | 0.778 | 1.000(0.999~1.001) |
A/G比值 | 0.019 | 0.259 | 0.006 | 0.940 | 1.020(0.614~1.693) |
项目 | B值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
hs-cTnT | 0.006 | 0.002 | 10.114 | 0.001 | 1.006 (1.002~1.009) |
Alb | -0.199 | 0.037 | 28.575 | 0.000 | 0.820 (0.762~0.882) |
LDH | 0.000 | 0.000 | 0.342 | 0.558 | 1.000(1.000~1.001) |
MYO | 0.000 | 0.001 | 0.079 | 0.778 | 1.000(0.999~1.001) |
A/G比值 | 0.019 | 0.259 | 0.006 | 0.940 | 1.020(0.614~1.693) |
[1] | 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].(2020-03-04)[2020-04-06]. . |
[2] | WANG D,HU B,HU C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020,323(11):1061-1069. |
[3] | HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet,2020,395(10223):497-506. |
[4] | 刘思嘉,程丰,杨晓玉,等. 鄂州市342例2019新型冠状病毒肺炎实验室确诊病例实验室检测指标与临床分型相关性分析[J/OL]. 检验医学(2020-04-02)[2020-04-06]. . |
[5] | 范久波,孙莉,何家富,等. SAA联合CRP、血常规检测在新型冠状病毒肺炎中的诊断价值[J]. 检验医学,2020,35(7):640-644. |
[6] | HAN H,XIE L,LIU R,et al.Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan,China[J]. J Med Virol,2020,92(7):819-823. |
[7] | GAO Y,LI T,HAN M,et al.Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19[J]. J Med Virol,2020,92(7):791-796. |
[8] | 黄傲,杨欣荣,孙惠川,等. 新型冠状病毒肺炎相关肝损伤的发生机制及防治措施[J] . 中华消化外科杂志,2020,19(3):248-250. |
[9] | 王云,赵长城,谷妍,等. 80例新型冠状病毒感染肺炎患者相关血液检测指标分析[J]. 临床输血与检验,2020,22(4):360-365. |
[10] | 刘映霞,杨扬,张聪,等. 新型冠状病毒(2019-nCoV)感染患者肺损伤相关的临床及生化指标研究[J]. 中国科学:生命科学,2020,50(3):258-269. |
[1] | YANG Xue, ZHU Jun, JIANG Lingli, WANG Qing, HU Xiaobo. Evaluation on the consistency of blind sample test results of 9 SARS-CoV-2 nucleic acid determination kits in Shanghai,China [J]. Laboratory Medicine, 2023, 38(8): 776-780. |
[2] | YU Qi, WANG Yanchun, GUO Lin, LU Renquan. Influence of particle radiotherapy on bone marrow,liver and kidney functions in patients with prostate cancer [J]. Laboratory Medicine, 2023, 38(5): 430-434. |
[3] | XIAO Xiumei, LIANG Chao, LIU Caihong, LI Xiaoguang. Comparison of SARS-CoV-2 neutralizing antibody and specific antibody determination results [J]. Laboratory Medicine, 2023, 38(4): 352-356. |
[4] | ZENG Yanfen, WU Quanming, ZHOU Huan, ZHANG Qiuqin, KANG Yanli, LI Yao, CHEN Xijun, HUANG Jiangang, CHEN Falin. Determination limits of a severe acute respiratory syndrome coronavirus 2 nucleic acid determination reagent in 4 determination systems [J]. Laboratory Medicine, 2023, 38(3): 261-266. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | YANG Danping, WANG Hong, WANG Can, CHEN Wei, YANG Aiping. Diagnostic efficacy and clinical application evaluation of SARS-CoV-2 antigen determination [J]. Laboratory Medicine, 2023, 38(1): 28-31. |
[8] | YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93. |
[9] | TAN Meiyu, SHU Jie, XUAN Binbin, ZHOU Lida, LI Hong, HOU Shangwei, SHENG Huiming. Effects of SARS-CoV-2 vaccination on antibody production and immune function [J]. Laboratory Medicine, 2022, 37(8): 729-734. |
[10] | CHEN Qian, SHAN Zhiming, SONG Chao, KANG Fengfeng, JIN Jing, LI Weixing. Status of quality management of new laboratories for nucleic acid determination of SARS-CoV-2 in Zhejiang [J]. Laboratory Medicine, 2022, 37(7): 669-673. |
[11] | SUN Jiaqi, JIN Weifeng, LI Ping, CHEN Shuzi, LIN Ping, LI Dan, CHEN Qing, WANG Mengxia, ZHU Yuxin. Influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring [J]. Laboratory Medicine, 2022, 37(12): 1174-1177. |
[12] | GE Yanmei, HAN Jianxiang, JI Wenli, GAO Daqing, TONG Huacheng. Analysis of serum SARS-CoV-2 IgM,IgG and neutralizing antibody levels in an adult population vaccinated with SARS-CoV-2 [J]. Laboratory Medicine, 2022, 37(1): 47-50. |
[13] | ZHANG Yunli, WANG Xin, SHAO Ling, QU Bo, ZHAO Hongmei. Comparison of different nucleic acid extraction methods for the detection of SARS-Cov-2 [J]. Laboratory Medicine, 2021, 36(5): 530-534. |
[14] | HUANG Fei, ZHANG Chunyan, GUO Wei, PAN Baishen, WANG Beili. Status and problems of SARS-CoV-2 nucleic acid detection [J]. Laboratory Medicine, 2021, 36(5): 554-559. |
[15] | CHEN Jianbo, YANG Yong, LI Huiyuan, REN Chanjun, DU Juan, LI Genshi, TAO Ran, CHEN Jingxian, ZHANG Ling, LI Miao. Comparison of 4 commercial kits for detecting SARS-CoV-2 nucleic acid [J]. Laboratory Medicine, 2021, 36(4): 396-399. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||